Volume 11, Issue 2 (6-2023)                   JoMMID 2023, 11(2): 103-109 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kumar Sharma R, Monica M, Chakraborty A. Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples. JoMMID 2023; 11 (2) :103-109
URL: http://jommid.pasteur.ac.ir/article-1-508-en.html
Antimicrobial Activity of Ceftazidime-Avibactam (CAZ-AVI) among the Carbapenemase-Producing Gram-negative Rods Isolated from Clinical Samples
Ravi Kumar Sharma , Monica Monica , Arindam Chakraborty
Department of Microbiology, Motilal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Abstract:   (1033 Views)
Introduction: Treating Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs), AmpC Beta lactamases, and carbapenemases is a significant clinical concern worldwide. To address this concern, Ceftazidime-Avibactam has been approved by the United States Food and Drug Administration (USFDA) as a practical option for combating multi-drug resistant (MDR) and extensively drug-resistant (XDR) organisms. Our study focused on determining the extent to which MDR Gram-negative organisms from various clinical samples exhibited resistance to CAZ-AVI. Methods: Conducted at a central India tertiary care teaching hospital, our prospective study analyzed 258 Gram-negative bacteria specimens. These bacterial strains were identified using standard biochemical tests. ESBL production was detected using the combination disk method, while the AmpC enzyme was detected using the Epsilometer test (E-test). Furthermore, we assessed carbapenemase production using disk diffusion methods. Our study used the E-test to identify Metallo-beta-lactamases and Klebsiella pneumonia carbapenemase (KPC) activity. Additionally, we utilized the E-test to analyze the susceptibility patterns of CAZ-AVI. Results: Of the 258 Gram-negative isolates studied, 214 (83%) were ESBL producers. Among these isolates, 90 (35%) showed evidence of AmpC beta-lactamase production, with 17 (19%) being pure AmpC producers and 73 (81%) being ESBL co-producers. 55 (21.50%) were found to be carbapenemase producers. Among these isolates, 34 (62%) were MBL producers, while 11 (20%) were KPC producers. Of the carbapenemase-producing isolates, 14 (25.50%) were resistant to CAZ-AVI. Among the MDR isolates, we found that CI 109 (90%), PB 118 (97.50%), and FO 113 (93.50%) were the most effective antimicrobial agents. Conclusions: Gram-negative organisms that produce ESBL, AmpC, Carbapenemase, MBL, and KPC are particularly challenging for clinicians and a significant threat worldwide. However, our study results suggest that CAZ-AVI could be an effective standard therapy for managing MDR Gram-negative organisms. 
Keywords: CAZ-AVI, Carbapenemase, MBL, MDR, Gram-negative organism
Full-Text [PDF 687 kb]   (541 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2022/11/16 | Accepted: 2023/06/11 | Published: 2023/07/18
References
1. Theuretzbacher, U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017; 39: 106-12. [DOI:10.1016/j.mib.2017.10.028] [PMID]
2. Lascols C, Hackel M, Marshall HS, Hujer AM, Bouchillon S, Badal R, et al. Increasing prevalence and dissemination of NDM-1metallo β lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 2011; 66 (9): 1992-7. [DOI:10.1093/jac/dkr240] [PMID] [PMCID]
3. Shankar C, Jacob JJ, Sugumar SG, Natarajan L, Rodrigues C, Mathur P, et al. Distinctive mobile genetic elements observed in the clonal expansion of carbapenem-resistant Klebsiella pneumoniae in India. Microb Drug Resist. 2021; 27 (8): 1096-104. [DOI:10.1089/mdr.2020.0316] [PMID]
4. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73 (2): 159-77. [DOI:10.1007/s40265-013-0013-7] [PMID]
5. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018; 73 (6): 1525-9. [DOI:10.1093/jac/dky082] [PMID]
6. Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T, et al. Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics (Basel). 2022; 6; 11 (5): 628. [DOI:10.3390/antibiotics11050628] [PMID] [PMCID]
7. Chakraborty A, Adhikari P, Shenoy S, Baliga S, Rao SBD, Saralaya V. Expression of ESBL, MBL and AmpC B lactamases by extraintestinal Escherichia coli isolates correlation with treatment and clinical outcome. J Microbiol Infect Dis. 2013; 3 (04): 150-6. [DOI:10.5799/ahinjs.02.2013.04.0100]
8. Clinical and laboratory standards institute. 2021. Performance standards for antimicrobial susceptibility testing. CLSI M100-Ed31. Update March 2021. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
9. DevangaRagupathi NK, Veeraraghavan B, MuthuirulandiSethuvel DP, Anandan S, Vasudevan K, Neeravi AR, et al. First Indian report on genome-wide comparison of multidrug-resistant Escherichia coli from bloodstream infections. PLoS One. 2020; 15 (2): e0220428. [DOI:10.1371/journal.pone.0220428] [PMID] [PMCID]
10. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Kempegowda P. Clinico-microbiological profile of urinary tract infection in south India. Indian J Nephrol. 2011; 21 (1): 30-6. [DOI:10.4103/0971-4065.75226] [PMID] [PMCID]
11. Kamat US, Fereirra A, Amonkar D, Motghare DD, Kulkarni MS. Epidemiology of hospital-acquired urinary tract infections in a medical college hospital in Goa. Indian J Urol. 2009; 25 (1): 76-80. [DOI:10.4103/0970-1591.45542] [PMID] [PMCID]
12. Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B. Prevalence of ESBL in Escherichia coli Isolates Among ICU Patients in a Tertiary Care Hospital. J Clin Diagn Res. 2016; 10 (9): DC19-DC22. [DOI:10.7860/JCDR/2016/21260.8544] [PMID] [PMCID]
13. Gajamer VR, Bhattacharjee A, Paul D, Ingti B, Sarkar A, Kapil J, et al. High prevalence of carbapenemase, AmpC β-lactamase, and aminoglycoside resistance genes in extended-spectrum β-lactamase-positive uropathogens from Northern India. J Glob Antimicrob Resist. 2020; 20: 197-203. [DOI:10.1016/j.jgar.2019.07.029] [PMID]
14. Chakraborty A, Adhikari P, Shenoy S, Rao S, Dhanashree B, Saralaya V. Molecular characterization and clinical significance of extraintestinal pathogenic Escherichia coli recovered from a south Indian tertiary care hospital. Microb Pathog. 2016; 95: 43-8. [DOI:10.1016/j.micpath.2016.03.001] [PMID]
15. Chakraborty A, Adhikari P, Shenoy S, Saralaya V. Characterization of plasmid-mediated AmpC producing Escherichia coli clinical isolates from a tertiary care hospital in South India. Indian J Pathol Microbiol. 2014; 57 (2): 255-8 [DOI:10.4103/0377-4929.134700] [PMID]
16. Ghosh B, Mukherjee M. Emergence of co-production of plasmid-mediated AmpC beta-lactamase and ESBL in cefoxitin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol Infect Dis. 2016; 35 (9): 1449-54. [DOI:10.1007/s10096-016-2683-z] [PMID]
17. Rafiee R, Eftekhar F, Tabatabaei SA, MinaeeTehrani D. Prevalence of Extended-Spectrum and Metallo β-Lactamase Production in AmpC β-Lactamase Producing Pseudomonas aeruginosa Isolates From Burns. Jundishapur J Microbiol. 2014; 7 (9): e16436. [DOI:10.5812/jjm.16436] [PMID] [PMCID]
18. Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016; 6 (8): a025247. [DOI:10.1101/cshperspect.a025247] [PMID] [PMCID]
19. Bakthavatchalam YD, Routray A, Mane A, Kamat S, Gupta A, Bari AK, et al. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem-resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. Diagn Microbiol Infect Dis. 2022; 103 (1): 115652. [DOI:10.1016/j.diagmicrobio.2022.115652] [PMID]
20. Vamsi SK, Moorthy RS, Hemiliamma MN, Chandra Reddy RB, Chanderakant DJ, Sirikonda S. Phenotypic and genotypic detection of carbapenemase production among Gram-negative bacteria isolated from hospital-acquired infections. Saudi Med J. 2022; 43 (3): 236-43. [DOI:10.15537/smj.2022.43.3.20210809] [PMID] [PMCID]
21. Radhika A, Lakshmi JT, Ariyanachi K, Sakthivadivel V. Detection of Metallo Beta-Lactamase (MBL) Producing Pseudomonas aeruginosa in a Tertiary Care Hospital, Ghanpur, Medchal, India. Maedica (Bucur). 2022; 17 (1): 134-42.
22. Meletis G. Carbapenem resistance: an overview of the problem and future perspectives. Ther Adv Infect Dis. 2016; 3 (1): 15-21. [DOI:10.1177/2049936115621709] [PMID] [PMCID]
23. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021; 72 (7): e169-e83. [DOI:10.1093/cid/ciaa1478] [PMID]
24. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019; 69 (Suppl 7): 565-75. [DOI:10.1093/cid/ciz830] [PMID] [PMCID]
25. Rathish B, Wilson A, Warrier A, Prakash S, Babu R, Joy S. Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study. Cureus. 2021; 13 (2): e13081. [DOI:10.7759/cureus.13081]
26. Swaminathan S, Routray A, Mane A. Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario. Cureus. 2022; 14 (8): e28283. [DOI:10.7759/cureus.28283]
27. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020; 22: 18-27. [DOI:10.1016/j.jgar.2019.12.009] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.